Transtech Pharma, Inc.

Jeffrey C Webster

Adnan M M Mjalli

Robert Rothlein

Ye Edward Tian

Eric Joel Benjamin

Adnan MM Mjalli

Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.

Rage fusion proteins and methods of use

Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin C2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.

Nucleic acid molecules encoding rage fusion proteins

RAGE fusion proteins, formulations, and methods of use thereof

Rage fusion proteins

Growing community of inventors

Jamestown, NC, United States of America

Jeffrey C Webster